Bengt Westrin

Dr Bengt Westrin joined Ventac Partners in June 2010. He has over 25 years industry experience, spanning from startups to big pharma, from product development and regulatory affairs to project management and business development. Prior to joining Ventac Partners he was CEO at the Karolinska Development company Lipopeptide AB in Stockholm and prior to that, VP Business Development at the drug delivery company Camurus AB* in Lund, Sweden. During 2009 to 2014 he was CEO of Idogen AB* which was co-founded by Ventac Partners in 2008, and was then Chairman of the Idogen Board until March 2015. He has also been CEO of the Swedish companies AcuCort AB* which developed a reformulated oral glucocorticoid product, and CombiGene AB* which is developing an AAV gene therapy against epilepsy, and has also had numerous consultancy assignment for other public or private companies. Dr Westrin received his MSc and his PhD at the Faculty of Engineering at Lund University, where he is also Associate Professor since 1999. *) public and listed.

Subscribe to our Newsletter

Thank you!